Oxford Brookes University

Set in a historic student city, Oxford Brookes enjoys an international reputation for teaching excellence and innovation as well as strong links with business and industry. We are widely acknowledged to be the UK's leading modern university, surpassing many older institutions in newspaper league tables. Whilst we are proud of these accolades, our vision is simply to offer our students one of the very best university experiences.  The University can trace its history back as far as 1865 with the foundation of the Oxford School of Art, which over the centuries merged and grew to become today's university. As Oxford Polytechnic, it was a pioneer of modular degrees that cut across departmental boundaries.  It was in 1992 that Oxford Polytechnic became Oxford Brookes University, naming itself after John Henry Brookes, first Principal of the Schools of Technology, Art and Commerce.

Within the university, the Department of Biological and Medical Sciences has consistently been one of the most successful in attracting research grants (e.g. from the BBSRC) and consultancy.



After studying biochemistry at Oxford University, followed by a DPhil on the physical biochemistry of yeast pyruvate kinase, he started lecturing at Oxford Polytechnic.  His research moved from enzymology into computer simulation and theoretical analysis of metabolic control, and he has written the only textbook on metabolic control analysis, Understanding the Control of Metabolism.  He has pioneered developments in the analysis of the structure of metabolic networks, and his computer modelling has extended into signal transduction pathways and the cell cycle. He leads the Cell Systems Modelling Group whose recent research projects include genome-scale metabolic modelling of bacteria including Salmonella, and of Arabidopsis and rice, the latter two  in collaboration with colleagues at the Universities of Oxford and Calcutta.

In 2001, he helped to found and became part-time Chief Scientific Officer of the Oxford company Physiomics plc, which is using computer simulation of cellular systems for the development and analysis of therapeutic strategies for the pharmaceutical industry.

David has been a member of a number of editorial boards, including the Biochemical Journal, the European Journal of Biochemistry (FEBS Journal) and Metabolic Engineering.  He is the chairman of the Policy Committee of the Biochemical Society.  For the Biotechnology and Biological Sciences Research Council in the UK he has been a member of the Engineering and Biological Systems Committee, chair of Integrated and Systems Biology Strategy Panel and is currently a member of the Industrial Biotechnology and Bioenergy Strategy Panel.